NEUROONE MEDICAL TECHNOLOGIES Corp — fact timeline

NEUROONE MEDICAL TECHNOLOGIES Corp reported that prior financial statements should not be relied upon.

“On May 21, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of NeuroOne Medical Technologies Corporation (the “Company”), after discussion with management, determined that the Company’s previously issued interim financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed on May 12, 2026 (the “Previous Filing”), should no longer be relied upon and should be restated because of accounting errors relating to revenue recognition.”

NEUROONE MEDICAL TECHNOLOGIES Corp reported financial results for the fiscal quarter ended March 31, 2026.

“On May 12, 2026, NeuroOne Medical Technologies Corporation (the "Company") issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026.”

Christopher Volker was appointed as Chief Financial Officer at NEUROONE MEDICAL TECHNOLOGIES Corp.

“the Board announced that Christopher Volker, the Company’s Chief Operating Officer, will succeed Mr. McClurg as the Company’s Chief Financial Officer effective as of July 1, 2026.”

Ronald McClurg departed as Chief Financial Officer at NEUROONE MEDICAL TECHNOLOGIES Corp.

“On April 24, 2026, Ronald McClurg notified NeuroOne Medical Technologies Corporation (the "Company") of his intention to retire as the Company’s Chief Financial Officer.”

NEUROONE MEDICAL TECHNOLOGIES Corp: Certificate of Amendment filed to effect a 1-for-6 reverse stock split of common stock (effective 2026-04-15).

“On April 14, 2026, NeuroOne Medical Technologies Corporation (the “Company” or “NeuroOne”) filed an amendment to its Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”).”

NEUROONE MEDICAL TECHNOLOGIES Corp received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“November 4, 2025, NeuroOne Medical Technologies Corporation (the “Company”) received a letter (the “Extension Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that Nasdaq has granted the Company a 180-day extension, until May 4, 2026 (the “Extension Period”), to regain compliance with the requirement for the Company’s common stock, par value $0.001 per share (“Common Stock”), to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Mi”

NEUROONE MEDICAL TECHNOLOGIES Corp received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 8, 2025, the Company received a letter from the Staff indicating the Company’s continued non-compliance with the Minimum Bid Price Requirement. The letter further informed the Company that the Company’s common stock would be delisted from The Nasdaq Capital Market unless the Company appeals the Staff’s delisting determination by requesting a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company’s request for a hearing will stay any further delisting action by the Staff pending the ultimate outcome of the hearing. The Company’s common stock will remain listed and eligible”

NEUROONE MEDICAL TECHNOLOGIES Corp received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 8, 2025, the Company received a letter from the Staff indicating the Company’s continued non-compliance with the Minimum Bid Price Requirement. The letter further informed the Company that the Company’s common st”

NEUROONE MEDICAL TECHNOLOGIES Corp reported second quarter fiscal year 2024 ended March 31, 2024 results: revenue $1,377,000, net income $2.9 million.

“results for the second quarter fiscal year 2024 ended March 31, 2024. Second Quarter Fiscal Year 2024 and Recent Business Updates Financial Highlights: ● Product revenue of $1,377,000 in Q2 2024, compared to $466,000 in Q2 2023 ● Raised an additional $2.0 million using the ATM Program in Q2 2024 Evo ® sEEG: ● Zimmer Biomet continued to expand into new”

NEUROONE MEDICAL TECHNOLOGIES Corp shareholders approved Advisory approval of frequency of future advisory votes on executive compensation: every three years (the frequency receiving the majority of votes cast) at the 2024-03-14 meeting.

“Proposal 4—Advisory Approval of the Frequency of an Advisory Vote on Named Executive Officers Compensation One Year Two Years Three Years Votes Abstain 3,060,695 144,245 3,723,836 239,241 For Proposal 4, “every three years” received the affirmative vote of the holders of a majority of the voting power of shares present”

NEUROONE MEDICAL TECHNOLOGIES Corp shareholders approved Approval of the Company's named executive officers' compensation in an advisory vote at the 2024-03-14 meeting.

“Proposal 3—Approval of the Company’s Named Executive Officers’ Compensation in an Advisory Vote Votes For Votes Against Votes Abstain 6,586,582 330,506 250,929”

NEUROONE MEDICAL TECHNOLOGIES Corp shareholders approved Ratification of appointment of Baker Tilly U.S., LLP as independent registered public accounting firm for fiscal year ending September 30, 2024 at the 2024-03-14 meeting.

“Proposal 2—Ratification of Appointment of Independent Registered Public Accounting Firm Votes For Votes Against Votes Abstain 15,736,069 36,991 9,364”

NEUROONE MEDICAL TECHNOLOGIES Corp shareholders approved Election of Class I director Paul Buckman at the 2024-03-14 meeting.

“Proposal 1—Election of Directors Class I Nominee Votes For Votes Withheld Broker Non-Votes Paul Buckman 5,804,908 1,363,109 8,614,407”

NEUROONE MEDICAL TECHNOLOGIES Corp reported financial results for first quarter fiscal year 2024 ended December 31, 2023.

“On February 13, 2024, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2023.”

NEUROONE MEDICAL TECHNOLOGIES Corp reported full fiscal year ended September 30, 2023 results: revenue Product revenue of $1,952,000 for FY 2023, net income Net loss was $11.9 million for the full year fiscal 2023.

“today announces its operating results for the fiscal fourth quarter and full fiscal year ended September 30, 2023.”

NEUROONE MEDICAL TECHNOLOGIES Corp reported fiscal fourth quarter and full fiscal year ended September 30, 2023 results: revenue Product revenue of $742,000 in Q4 2023, net income Net loss was $3.1 million for the fourth quarter of fiscal 2023.

“On December 14, 2023, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter and fiscal year ended September 30, 2023.”

Christopher R. Volker was appointed as Chief Operating Officer at NEUROONE MEDICAL TECHNOLOGIES Corp.

“Christopher R. Volker, age 52, has been appointed as the Chief Operating Officer of the Company, effective on November 10, 2023.”

NEUROONE MEDICAL TECHNOLOGIES Corp reported fiscal third quarter 2023 ended June 30, 2023 results: revenue Product revenue was $630,000 in the fiscal third quarter 2023, net income Net loss was $3.5 million for the fiscal third quarter 2023.

“On August 14, 2023, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.”

NEUROONE MEDICAL TECHNOLOGIES Corp entered into Underwriting Agreement with The Benchmark Company, LLC valued at approximately $5,214,875 (effective 2023-07-24).

“On July 24, 2023, NeuroOne Medical Technologies Corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with The Benchmark Company, LLC, as underwriter (the “Underwriter”), relating to the issuance and sale of 5,250,000 shares of the Company’s common stock, par value $0.001 per share, at a price to the public of $1.00 per share.”

NEUROONE MEDICAL TECHNOLOGIES Corp reported fiscal second quarter 2023 ended March 31, 2023 results: revenue product revenue was $466,000, net income Net loss was $3.5 million for the fiscal second quarter 2023.

“Product revenue was $466,000 in the fiscal second quarter 2023, compared to product revenue of $37,000 in the fiscal second quarter 2022.”

NEUROONE MEDICAL TECHNOLOGIES Corp shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-03-16 meeting.

“Proposal 2—Ratification of Appointment of Independent Registered Public Accounting Firm Votes For Votes Against Votes Abstain 9,661,674 45,763 12,037”

NEUROONE MEDICAL TECHNOLOGIES Corp shareholders approved Election of Class III Directors at the 2023-03-16 meeting.

“Proposal 1—Election of Directors Class III Nominees Votes For Votes Withheld Broker Non-Votes Jeffrey Mathiesen 4,309,601 268,402 5,141,471 Edward Andrle 3,474,438 1,103,565 5,141,471”

NEUROONE MEDICAL TECHNOLOGIES Corp reported financial results for the fiscal first quarter 2023 ended December 31, 2022.

“On February 14, 2023, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2022.”

NEUROONE MEDICAL TECHNOLOGIES Corp reported fiscal year ended September 30, 2022 results: net income $10.0 million.

“Net loss was $10.0 million for the full year fiscal 2022, compared to a net loss of $9.9 million in fiscal 2021.”

NEUROONE MEDICAL TECHNOLOGIES Corp reported fiscal fourth quarter ended September 30, 2022 results: net income $1.4 million.

“Net loss was $1.4 million for the fourth quarter of fiscal 2022, compared to a net loss of $2.6 million in the prior year period.”